Israel Englander Roivant Sciences Ltd. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $2.11 Million - $2.39 Million	-203,719 Reduced 52.5%	184,343 $1.95 Million
Q1 2024 May 15, 2024	SELL	$9.87 - $11.8 $7.12 Million - $8.51 Million	-721,117 Reduced 65.01%	388,062 $4.09 Million
Q4 2023 Feb 14, 2024	SELL	$8.38 - $11.58 $4.92 Million - $6.8 Million	-586,797 Reduced 34.6%	1,109,179 $12.5 Million
Q2 2023 Aug 14, 2023	BUY	$7.09 - $10.08 $9.13 Million - $13 Million	1,287,479 Added 315.17%	1,695,976 $17.1 Million
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $2.39 Million - $3.45 Million	345,606 Added 549.53%	408,497 $3.02 Million
Q4 2022 Feb 14, 2023	SELL	$3.36 - $7.99 $69,877 - $166,168	-20,797 Reduced 24.85%	62,891 $502,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $42,680 - $405,049	83,688 New	83,688 $269,000

310

507M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.15B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.